XTALPI's stock soared 5.07% intraday on Wednesday, marking a significant rebound in trading activity.

The surge is attributed to a volume-driven rebound following a post-earnings correction. This movement comes after the company reported robust annual results, including revenue that surged over 200% year-on-year and its first-ever annual profit. Additionally, XTALPI has successfully expanded beyond AI-powered drug discovery into broader material science, securing strategic partnerships with major enterprises such as CATL for solid-state battery material optimization and GCL Group for photovoltaic material R&D. The company's revenue model has also evolved to include upfront payments, milestone fees, and royalties, highlighted by landmark deals like a USD 1.835 billion out-licensing agreement.

Within the sector, performance was mixed, with some peers gaining while others declined, but XTALPI's strong fundamentals and strategic initiatives appear to have driven investor confidence and the intraday price increase.